Core Insights - Zimmer Biomet Holdings, Inc. (ZBH) has a market capitalization of $18.8 billion and specializes in orthopedic reconstructive products, sports medicine solutions, biologics, and surgical technologies, serving healthcare professionals globally [1] Financial Performance - The company is expected to announce its fiscal Q3 2025 results on November 5, with analysts predicting an adjusted EPS of $1.87, reflecting a 7.5% increase from $1.74 in the same quarter last year [2] - For fiscal 2025, adjusted EPS is projected to be $8.15, a 1.9% increase from $8 in fiscal 2024, with further growth anticipated to $8.42 in fiscal 2026, representing a 3.3% year-over-year increase [3] Stock Performance - Zimmer Biomet's shares have decreased by 7.9% over the past 52 weeks, underperforming the S&P 500 Index, which increased by 13.4%, and the Health Care Select Sector SPDR Fund, which declined by 7.6% during the same period [4] - Following the release of better-than-expected Q2 2025 results, shares rose nearly 8% on August 7, with adjusted EPS reported at $2.07 and revenue at $2.08 billion. The company also raised its 2025 adjusted EPS forecast to between $8.10 and $8.30, exceeding analyst expectations [5] Analyst Ratings - The consensus rating for ZBH stock is "Moderate Buy," with 27 analysts covering the stock: eight recommend "Strong Buy," two suggest "Moderate Buy," 15 give a "Hold" rating, and two have a "Strong Sell" rating. The average price target is $110.74, indicating a potential upside of 16% from current levels [6]